\
&
Contact us
\
&
Contact us
The rules for project implementation are set-out in a Grant Agreement. NCP Flanders guides and supports you with all legal and financial issues during the complete life cycle of Horizon Europe.
All specific Legal&Finance news, documents, events, ...regarding Horizon 2020 can be found on the dedicated Horizon 2020 page on our website.
The administrative and financial framework with the rules for application and project implementation of Horizon Europe calls are set-out in a Grant Agreement. The latest draft of the Annotated Model Grant Agreement provides extensive explanation of the rules.
In the Online Manual extensive details can be found regarding the application process as well as the Grant Management, thus in-depth explanations about reporting, amendments, deliverables, dissemination&exploitation, etc. The manual is expected to be complemented throughout the programming period.
All available reference documents of Horizon Europe can be found on the Funding and Tender Portal.
ann.vanhauwaert@fwo.be
+32 2 550 15 60
Ria.debreucker@vlaio.be
+32 2 553 13 77
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
